Cariprazine

Introduction Overview

Generic Name

cariprazine

Brand Name

Vraylar

Dosage Form

capsules (1.5 mg, 3 mg, 4.5 mg, 6 mg)

Drug Class

Atypical antipsychotics

Pharmacokinetics

Absorption:
Cariprazine is rapidly absorbed following oral administration, with peak plasma concentrations generally reached within 3 to 6 hours post-dose. The oral bioavailability is relatively high, facilitating effective systemic exposure. Food does not significantly affect the absorption of cariprazine, permitting administration with or without meals. Factors such as gastrointestinal motility and pH are not expected to markedly influence the absorption profile.

Distribution:
Cariprazine exhibits extensive distribution throughout the body, with a large apparent volume of distribution (approximately 20 to 25 L/kg), indicating significant tissue uptake. It is highly lipophilic, allowing penetration across the blood-brain barrier to exert central nervous system effects. Cariprazine is extensively bound to plasma proteins (~91-97%), primarily albumin and alpha-1 acid glycoprotein, which contributes to its pharmacologic activity and distribution balance.

Metabolism:
Metabolism of cariprazine occurs primarily in the liver via CYP450 enzymes, predominantly CYP3A4 and to a lesser extent CYP2D6. It undergoes extensive biotransformation to two major active metabolites: desmethyl-cariprazine (DCAR) and didesmethyl-cariprazine (DDCAR), both contributing significantly to the overall pharmacological effects due to their activity at dopamine and serotonin receptors. These metabolites have longer elimination half-lives than cariprazine itself, prolonging the clinical effects and necessitating careful dose titration.

Elimination:
Cariprazine and its metabolites are eliminated mainly via hepatic metabolism followed by renal and fecal excretion. The effective half-life of cariprazine ranges from approximately 2 to 4 days, while its active metabolites, especially DDCAR, have effective half-lives up to 1 to 3 weeks, which explains the prolonged duration of action and the persistence of side effects after discontinuation. Steady-state concentrations are typically achieved after several weeks of consistent dosing. Careful consideration is needed in patients with hepatic impairment as metabolism may be affected.

Dosage Forms

Available Dosage Forms:
Vraylar is available as oral capsules in the following strengths: 1.5 mg, 3 mg, 4.5 mg, and 6 mg. The capsules contain cariprazine as the active ingredient with inactive excipients including gelatin, magnesium stearate, pregelatinized starch, shellac, titanium dioxide, and colorants such as black iron oxide, FD&C Blue 1, FD&C Red 3, FD&C Red 40, or yellow iron oxide.

Dosages for Adults and Adolescents:
The recommended starting dose for adults varies depending on the indication; typical initiation is at 1.5 mg once daily with titration up to 6 mg/day based on clinical response and tolerability. For schizophrenia and bipolar I disorder, dose adjustments generally range between 1.5 mg to 6 mg daily. In major depressive disorder as adjunct therapy, careful titration is advised, with the typical maintenance dose around 1.5 to 3 mg daily.

Specific Patient Populations:
Vraylar is not approved for use in pediatric patients under 18 years of age. In elderly patients, particularly those with dementia-related psychosis, Vraylar is contraindicated due to increased risk of mortality. Dose adjustments may be necessary in patients with hepatic impairment, although specific guidelines recommend cautious use and monitoring. Renal impairment has minimal effect on pharmacokinetics, but clinical monitoring is still prudent. No specific dosage forms or dosing adjustments are provided for pediatric or geriatric populations outside these considerations.

Mechanism Of Action

Cariprazine is an atypical antipsychotic agent that exerts its therapeutic effects primarily through partial agonism at central dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, as well as antagonism at serotonin 5-HT2A receptors. This receptor binding profile allows modulation of dopaminergic and serotonergic neurotransmission, which is implicated in the pathophysiology of schizophrenia, bipolar disorder, and major depressive disorder.

The partial agonist activity at dopamine D3 receptors differentiates cariprazine from many other antipsychotics. Dopamine D3 receptors are predominantly located in the ventral striatum, an area involved in motivation and reward pathways, and modulation here may contribute to improved negative symptoms and cognitive deficits associated with schizophrenia. This selective receptor targeting may also reduce the incidence of extrapyramidal symptoms compared to typical antipsychotics.

Cariprazine’s antagonism of serotonin 5-HT2A receptors contributes to the overall antipsychotic effects by balancing dopamine activity in certain brain regions and improving mood symptoms. Additionally, agonism at serotonin 5-HT1A receptors is thought to contribute anxiolytic and antidepressant benefits, which may explain efficacy in bipolar depression and as adjunctive therapy in major depressive disorder.

Clinical studies demonstrate that the combination of these receptor activities results in improved psychiatric symptoms including hallucinations, delusions, mood stabilization, and depressive symptoms. Compared to other atypical antipsychotics such as aripiprazole, cariprazine’s preferential D3 receptor partial agonism provides a unique neuropharmacologic profile with potentially enhanced therapeutic benefits and a distinct side effect profile. Research continues to elucidate the full scope of clinical applications based on these mechanisms.

Pharmacological Actions

Partial agonist at dopamine D2 and D3 receptors, modulating dopaminergic neurotransmission.
Partial agonist at serotonin 5-HT1A receptors, contributing to anxiolytic and antidepressant effects.
Antagonist at serotonin 5-HT2A receptors, balancing serotonergic activity and improving mood symptoms.
Potent binding with preferential affinity for D3 receptors, impacting motivational and cognitive pathways.
Exerts antipsychotic effects by normalizing dysregulated dopamine activity implicated in schizophrenia and bipolar disorder.
Mood stabilizing properties useful in treating acute manic and depressive episodes in bipolar I disorder.
Adjunctive antidepressant effects when combined with antidepressants in treatment-resistant major depressive disorder.
Reduced propensity to cause extrapyramidal symptoms compared to typical antipsychotics due to balanced dopamine receptor activity.
Metabolically neutral profile, associated with relatively low risk of weight gain and metabolic syndrome among atypical antipsychotics.
Long half-life active metabolites contribute to sustained pharmacologic action and therapeutic effects.
Modulates neuronal circuits related to psychosis, mood regulation, cognition, and motivation.
May reduce suicidal ideation and behavior in mood disorder patients through broad psychotropic activity.

Therapeutic Or Clinical Uses

Treatment of schizophrenia in adults to improve positive and negative psychiatric symptoms.
Management of acute manic or mixed episodes associated with bipolar I disorder.
Treatment of depressive episodes associated with bipolar I disorder (bipolar depression).
Adjunctive therapy for major depressive disorder (MDD) in adults with inadequate response to antidepressant therapy alone.
Improvement of mood stabilization in bipolar disorder patients.
Reduction of psychotic symptoms such as hallucinations and delusions.
Improvement of negative symptoms and cognitive deficits in schizophrenia.
Potential benefits in treatment-resistant depressive symptoms through modulation of dopaminergic and serotonergic systems.
Management of mood swings and agitation associated with mental health disorders.
Off-label use guided by clinical discretion in certain psychotic and mood disorders, pending further research.

Side Or Adverse Effects

Common side effects include somnolence (sleepiness) and fatigue.
Gastrointestinal disturbances such as nausea, vomiting, indigestion, constipation, and upset stomach.
Dizziness and increased risk of orthostatic hypotension, especially during dose titration.
Involuntary muscle movements including tremors, akathisia (restlessness), and extrapyramidal symptoms.
Weight gain, although less pronounced compared to some other atypical antipsychotics.
Trouble sleeping (insomnia) or disturbed sleep patterns.
Restlessness and agitation, occasionally leading to increased anxiety.
Potential for serious neurological side effects such as tardive dyskinesia or neuroleptic malignant syndrome.
Rare allergic reactions manifesting as hives, swelling, or difficulty breathing.
Low white blood cell count leading to increased risk of infections, demonstrated by fever, chills, sore throat, and mouth sores.
Hyperglycemia or elevated blood sugar levels with states of polyuria, polydipsia, dry mouth, and fruity breath odor.
Difficulty swallowing and risk of aspiration pneumonia.
Possible seizure induction or lowered seizure threshold in susceptible individuals.
Long-lasting side effects that may persist for several weeks after discontinuation.
Postural dizziness increasing risk of falls and injuries, especially in elderly patients.

Precautions

Use cautiously in patients with a history of cardiovascular disease, hypertension, or stroke due to risk of orthostatic hypotension and cerebrovascular events.
Monitor blood glucose and lipid profiles periodically as cariprazine may affect metabolic parameters.
Assess for history of seizures and avoid use in uncontrolled seizure disorders.
Use with caution in patients with liver impairment as metabolism predominantly occurs hepatically.
Avoid abrupt discontinuation; taper doses slowly under medical supervision to reduce withdrawal or rebound symptoms.
Close monitoring for extrapyramidal symptoms and movement disorders, particularly with long-term use.
Regular weight monitoring is recommended due to risk of weight gain.
Consider fall risk in elderly patients due to dizziness and sedation.
Avoid use in elderly patients with dementia-related psychosis due to increased mortality risk.
Inform patients about potential delayed onset of therapeutic effects and the importance of adherence.
Exercise caution in patients at risk for dehydration or heat exposure due to possible impaired thermoregulation.
Monitor for signs of neuroleptic malignant syndrome or serotonin syndrome, which require immediate intervention.
Evaluate the potential risk of suicidal ideation especially in pediatric and young adult populations.
Avoid concomitant use with other CNS depressants without physician approval.
Inform women of childbearing potential about pregnancy registry and potential risks during pregnancy and lactation.

Warnings

Not approved for treatment of dementia-related psychosis in elderly patients; increased risk of death observed.
Risk of developing tardive dyskinesia, a potentially irreversible movement disorder, especially with prolonged high-dose therapy.
May impair the body's ability to regulate core body temperature, increasing risk of hyperthermia with heat exposure or strenuous exercise.
Potential for suicidal thoughts and behaviors especially in children, adolescents, and young adults during early treatment phases or dose changes.
May cause serious allergic reactions; seek emergency care if hives, facial swelling, or breathing difficulties occur.
Risk of neuroleptic malignant syndrome, characterized by muscle rigidity, hyperthermia, autonomic instability, and altered consciousness.
Severe extrapyramidal symptoms including uncontrolled muscle movements may require medical intervention.
Possible severe hyperglycemia and diabetic ketoacidosis in patients with or without prior diabetes history.
Avoid concomitant use with CNS depressants without careful monitoring due to additive sedation and respiratory depression.
Long half-life of metabolites may prolong side effects and complicate dosing adjustments or discontinuation.
May cause orthostatic hypotension leading to syncope or falls.
Careful monitoring necessary during pregnancy and lactation due to potential neonatal withdrawal symptoms.
Use caution when prescribing to patients with a history of blood dyscrasias or infections due to possible leukopenia or neutropenia.
Patients should avoid alcohol consumption while using Vraylar to prevent enhanced sedative effects.
Driving or operating machinery can be impaired due to dizziness or sedation; patients should be advised accordingly.

Contraindication

Known hypersensitivity or allergy to cariprazine or any components of the formulation.
Use in pediatric patients under 18 years of age as safety and efficacy have not been established.
Patients with dementia-related psychosis due to increased risk of mortality.
Concurrent use with other antipsychotic drugs contraindicated unless under strict medical supervision.
Severe hepatic impairment where metabolism and clearance may be significantly altered.
History of hypersensitivity reactions manifested by anaphylaxis or severe allergic responses to similar atypical antipsychotics.
Use is contraindicated during breastfeeding unless potential benefits outweigh risks, requiring medical supervision.
Avoid use in patients with known QT prolongation or cardiac arrhythmias without specialist consultation.
Not recommended for use in patients with severe dehydration or electrolyte imbalance without correction.
Concurrent use with medications that significantly inhibit CYP3A4 or CYP2D6 without dose adjustment or monitoring.

Drug Interactions

CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, protease inhibitors) can increase cariprazine plasma levels, raising risk of toxicity.
CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) may decrease cariprazine effectiveness by reducing blood concentration.
CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) may increase levels of cariprazine and its active metabolites.
Concomitant use with CNS depressants such as benzodiazepines, opioids, sedative-hypnotics can increase sedation and respiratory depression risk.
Use with other antipsychotics may raise the risk of additive side effects, including extrapyramidal symptoms and metabolic disturbances.
Concomitant use with antihypertensives may potentiate orthostatic hypotension.
Drugs that prolong QT interval should be used cautiously to avoid arrhythmias when combined with cariprazine.
Alcohol consumption can exacerbate sedation, dizziness, and cognitive impairment associated with cariprazine.
Medications that affect electrolyte balance (diuretics) may augment risk for cardiac adverse effects when used with cariprazine.
Caffeine does not have documented interaction but may worsen restlessness or insomnia when combined.
Herbal supplements inducing CYP3A4 (e.g., St. John's Wort) may reduce cariprazine levels and effectiveness.
Co-administration with drugs affecting prolactin levels should be monitored closely.
Potential interactions with drugs treating seizures due to cariprazine's effect on seizure threshold.
Careful monitoring required when used with antidepressants due to increased risk of serotonergic side effects.
Patients should disclose all medications and supplements to healthcare providers to avoid unidentified interactions.

Preparations Of The Drug

Cariprazine active ingredient encapsulated in gelatin capsules.
Available in strengths of 1.5 mg, 3 mg, 4.5 mg, and 6 mg doses.
Inactive ingredients include magnesium stearate and pregelatinized starch as excipients.
Capsule shell consists of shellac and titanium dioxide for stability and appearance.
Colorants used include black iron oxide, FD&C Blue 1, FD&C Red 3, FD&C Red 40, and yellow iron oxide.
Oral capsule formulation designed for once-daily dosing with or without food.
Packaged in blister packs or bottles for patient convenience and medication protection.
Storage recommended at room temperature, between 68°F to 77°F (20°C to 25°C), avoiding moisture and heat.
Manufactured under strict GMP standards by Forest Laboratories Ireland Limited.
Distributed in the USA by Allergan USA, Inc., ensuring supply chain integrity.
Includes patient and prescriber informational leaflets detailing usage, risks, and precautions.
Non-liquid formulation ensures dose accuracy and long shelf life compared to suspensions.
No available generic oral liquid or injectable forms, limiting dosage flexibility in certain patient populations.
Formulation designed for adult use only, with no pediatric formulations currently available.
Capsule shell color varies by dosage strength to facilitate identification and adherence.